232 related articles for article (PubMed ID: 22554312)
21. A GDF11/myostatin inhibitor, GDF11 propeptide-Fc, increases skeletal muscle mass and improves muscle strength in dystrophic mdx mice.
Jin Q; Qiao C; Li J; Xiao B; Li J; Xiao X
Skelet Muscle; 2019 May; 9(1):16. PubMed ID: 31133057
[TBL] [Abstract][Full Text] [Related]
22. Myostatin/activin blocking combined with exercise reconditions skeletal muscle expression profile of mdx mice.
Kainulainen H; Papaioannou KG; Silvennoinen M; Autio R; Saarela J; Oliveira BM; Nyqvist M; Pasternack A; 't Hoen PA; Kujala UM; Ritvos O; Hulmi JJ
Mol Cell Endocrinol; 2015 Jan; 399():131-42. PubMed ID: 25304272
[TBL] [Abstract][Full Text] [Related]
23. Co-Administration of Myostatin-Targeting siRNA and ActRIIB-Fc Fusion Protein Increases Masseter Muscle Mass and Fiber Size.
Bayarsaikhan O; Kawai N; Mori H; Kinouchi N; Nikawa T; Tanaka E
J Nutr Sci Vitaminol (Tokyo); 2017; 63(4):244-248. PubMed ID: 28978871
[TBL] [Abstract][Full Text] [Related]
24. Biological scaffold-mediated delivery of myostatin inhibitor promotes a regenerative immune response in an animal model of Duchenne muscular dystrophy.
Estrellas KM; Chung L; Cheu LA; Sadtler K; Majumdar S; Mula J; Wolf MT; Elisseeff JH; Wagner KR
J Biol Chem; 2018 Oct; 293(40):15594-15605. PubMed ID: 30139748
[TBL] [Abstract][Full Text] [Related]
25. Akt deficiency attenuates muscle size and function but not the response to ActRIIB inhibition.
Goncalves MD; Pistilli EE; Balduzzi A; Birnbaum MJ; Lachey J; Khurana TS; Ahima RS
PLoS One; 2010 Sep; 5(9):e12707. PubMed ID: 20856813
[TBL] [Abstract][Full Text] [Related]
26. Dystrophin-deficient dogs with reduced myostatin have unequal muscle growth and greater joint contractures.
Kornegay JN; Bogan DJ; Bogan JR; Dow JL; Wang J; Fan Z; Liu N; Warsing LC; Grange RW; Ahn M; Balog-Alvarez CJ; Cotten SW; Willis MS; Brinkmeyer-Langford C; Zhu H; Palandra J; Morris CA; Styner MA; Wagner KR
Skelet Muscle; 2016; 6():14. PubMed ID: 27047655
[TBL] [Abstract][Full Text] [Related]
27. Myostatin inhibition by a follistatin-derived peptide ameliorates the pathophysiology of muscular dystrophy model mice.
Tsuchida K
Acta Myol; 2008 Jul; 27(1):14-8. PubMed ID: 19108572
[TBL] [Abstract][Full Text] [Related]
28. Myostatin genetic inactivation inhibits myogenesis by muscle-derived stem cells in vitro but not when implanted in the mdx mouse muscle.
Tsao J; Vernet DA; Gelfand R; Kovanecz I; Nolazco G; Bruhn KW; Gonzalez-Cadavid NF
Stem Cell Res Ther; 2013 Jan; 4(1):4. PubMed ID: 23295128
[TBL] [Abstract][Full Text] [Related]
29. Gene expression profiling of skeletal muscles treated with a soluble activin type IIB receptor.
Rahimov F; King OD; Warsing LC; Powell RE; Emerson CP; Kunkel LM; Wagner KR
Physiol Genomics; 2011 Apr; 43(8):398-407. PubMed ID: 21266502
[TBL] [Abstract][Full Text] [Related]
30. Myostatin/activin pathway antagonism: molecular basis and therapeutic potential.
Han HQ; Zhou X; Mitch WE; Goldberg AL
Int J Biochem Cell Biol; 2013 Oct; 45(10):2333-47. PubMed ID: 23721881
[TBL] [Abstract][Full Text] [Related]
31. Altered bone-regulating myokine expression in skeletal muscle Of Duchenne muscular dystrophy mouse models.
Zhou S; Qian B; Wang L; Zhang C; Hogan MV; Li H
Muscle Nerve; 2018 Oct; 58(4):573-582. PubMed ID: 30028902
[TBL] [Abstract][Full Text] [Related]
32. The role of myostatin and activin receptor IIB in the regulation of unloading-induced myofiber type-specific skeletal muscle atrophy.
Babcock LW; Knoblauch M; Clarke MS
J Appl Physiol (1985); 2015 Sep; 119(6):633-42. PubMed ID: 26205544
[TBL] [Abstract][Full Text] [Related]
33. The function of Myostatin and strategies of Myostatin blockade-new hope for therapies aimed at promoting growth of skeletal muscle.
Patel K; Amthor H
Neuromuscul Disord; 2005 Feb; 15(2):117-26. PubMed ID: 15694133
[TBL] [Abstract][Full Text] [Related]
34. A soluble activin type IIB receptor improves function in a mouse model of amyotrophic lateral sclerosis.
Morrison BM; Lachey JL; Warsing LC; Ting BL; Pullen AE; Underwood KW; Kumar R; Sako D; Grinberg A; Wong V; Colantuoni E; Seehra JS; Wagner KR
Exp Neurol; 2009 Jun; 217(2):258-68. PubMed ID: 19285073
[TBL] [Abstract][Full Text] [Related]
35. Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice.
Nakatani M; Takehara Y; Sugino H; Matsumoto M; Hashimoto O; Hasegawa Y; Murakami T; Uezumi A; Takeda S; Noji S; Sunada Y; Tsuchida K
FASEB J; 2008 Feb; 22(2):477-87. PubMed ID: 17893249
[TBL] [Abstract][Full Text] [Related]
36. Molecular mechanisms involving IGF-1 and myostatin to induce muscle hypertrophy as a therapeutic strategy for Duchenne muscular dystrophy.
Patel K; Macharia R; Amthor H
Acta Myol; 2005 Dec; 24(3):230-41. PubMed ID: 16629058
[TBL] [Abstract][Full Text] [Related]
37. Preliminary investigation into a potential role for myostatin and its receptor (ActRIIB) in lean and obese horses and ponies.
Morrison PK; Bing C; Harris PA; Maltin CA; Grove-White D; Argo CM
PLoS One; 2014; 9(11):e112621. PubMed ID: 25390640
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of myostatin does not ameliorate disease features of severe spinal muscular atrophy mice.
Sumner CJ; Wee CD; Warsing LC; Choe DW; Ng AS; Lutz C; Wagner KR
Hum Mol Genet; 2009 Sep; 18(17):3145-52. PubMed ID: 19477958
[TBL] [Abstract][Full Text] [Related]
39. [Therapeutic strategies for muscular dystrophy by myostatin inhibition].
Sunada Y
Rinsho Shinkeigaku; 2006 Nov; 46(11):942-4. PubMed ID: 17432227
[TBL] [Abstract][Full Text] [Related]
40. [Myostatin blockade therapy for muscular atrophy].
Sunada Y
Brain Nerve; 2011 Nov; 63(11):1271-7. PubMed ID: 22068480
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
